Naoxintong capsule delay the progression of diabetic kidney disease: A real-world cohort study

Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

(2021) Guoyi Tang et al.   Acta Pharmaceutica Sinica B

Comparison of Traditional Chinese Medicine in the Long-Term Secondary Prevention for Patients with Ischemic Stroke: A Systematical Analysis

(2021) Jiali Li et al.   Frontiers in Pharmacology

Multiple protein and mRNA expression correlations in the rat cerebral cortex after ischemic injury and repair due to buchang naoxintong jiaonang (BNJ) intervention

(2020) Xin Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy

(2020) Enyu Wang et al.   PHARMACOLOGICAL RESEARCH

Integrated metabolomics and gut microbiome to the effects and mechanisms of naoxintong capsule on type 2 diabetes in rats

(2020) Zenghao Yan et al.   Scientific Reports

Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation

(2020) Yudi Zhang et al.   Oxidative Medicine and Cellular Longevity

Systematical Identification of the Protective Effect of Danhong Injection and BuChang NaoXinTong Capsules on Transcription Factors in Cerebral Ischemia Mice Brain

(2020) Jing Xu et al.   Oxidative Medicine and Cellular Longevity

Ferulic Acid Protects Hyperglycemia-Induced Kidney Damage by Regulating Oxidative Insult, Inflammation and Autophagy

(2019) Sayantani Chowdhury et al.   Frontiers in Pharmacology

The cardioprotective properties and the involved mechanisms of NaoXinTong Capsule

(2019) Jihong Han et al.   PHARMACOLOGICAL RESEARCH

Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice

(2019) Shu Yang et al.   BIOMEDICINE & PHARMACOTHERAPY

Naoxintong Capsule Inhibits the Development of Cardiovascular Pathological Changes in Bama Minipig Through Improving Gut Microbiota

(2019) Wei-jian Zhang et al.   Frontiers in Pharmacology

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020

(2019)   DIABETES CARE

Trial designs using real‐world data: The changing landscape of the regulatory approval process

(2019) Elodie Baumfeld Andre et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Simultaneous determination and qualitative analysis of six types of components in Naoxintong capsule by miniaturized matrix solid-phase dispersion extraction coupled with ultra high-performance liquid chromatography with photodiode array detection and qua

(2018) Huilin Wang et al.   JOURNAL OF SEPARATION SCIENCE

NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice

(2018) Shu Yang et al.   Scientific Reports

Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF-κB signaling pathway

(2018) Juan Bai et al.   Scientific Reports

Testing for funnel plot asymmetry of standardized mean differences

(2018) James E. Pustejovsky et al.   Research Synthesis Methods

Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes

(2017) Andrzej S. Krolewski et al.   KIDNEY INTERNATIONAL

Paeoniflorin ameliorates renal function in cyclophosphamide-induced mice via AMPK suppressed inflammation and apoptosis

(2016) Qiang Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

A Review of Propensity-Score Methods and Their Use in Cardiovascular Research

(2016) Saswata Deb et al.   CANADIAN JOURNAL OF CARDIOLOGY

Identification of “Multiple Components-Multiple Targets-Multiple Pathways” Associated with Naoxintong Capsule in the Treatment of Heart Diseases Using UPLC/Q-TOF-MS and Network Pharmacology

(2016) Xianghui Ma et al.   Evidence-based Complementary and Alternative Medicine

Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitis-induced acute renal injury

(2016) Peng Wang et al.   Molecular Medicine Reports

Hydroxysafflor Yellow A Ameliorates Renal Fibrosis by Suppressing TGF-β1-Induced Epithelial-to-Mesenchymal Transition

(2016) Naping Hu et al.   PLoS One

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes

(2015) Mark E. Molitch et al.   KIDNEY INTERNATIONAL

Have we reached the limits for the treatment of diabetic nephropathy?

(2014) Reza Hajhosseiny et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Stratified Fisher's exact test and its sample size calculation

(2013) Sin-Ho Jung   BIOMETRICAL JOURNAL

Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition

(2013) M. A. Schroijen et al.   DIABETOLOGIA

Amygdalin inhibits renal fibrosis in chronic kidney disease

(2013) JUNQI GUO et al.   Molecular Medicine Reports

Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes

(2012) Ran Choi et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

One-to-many propensity score matching in cohort studies

(2012) Jeremy A. Rassen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials

(2011) H.J. Lambers Heerspink et al.   NEPHRON CLINICAL PRACTICE